Upgrade to SI Premium - Free Trial

Vaxcyte, Inc (PCVX)

47.36 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/12/26)

Latest Headlines

Form 4 Vaxcyte, Inc. For: Jun 01 Filed by: Wassil Jim June 3, 2026 4:59 PM - SEC Filing Vaxcyte begins first human trial of Group A strep vaccine candidate June 2, 2026 4:05 PM - StreetInsider Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults June 2, 2026 4:05 PM - StreetInsider Form 144 Vaxcyte, Inc. Filed by: Wassil Jim June 1, 2026 4:26 PM - SEC Filing Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P. May 15, 2026 4:51 PM - SEC Filing Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: JANUS HENDERSON GROUP PLC May 15, 2026 12:38 PM - SEC Filing Form 10-Q Vaxcyte, Inc. For: Mar 31 May 6, 2026 4:13 PM - SEC Filing Form 8-K Vaxcyte, Inc. For: May 06 May 6, 2026 4:09 PM - SEC Filing Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update May 6, 2026 4:05 PM - StreetInsider Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: FMR LLC May 6, 2026 11:41 AM - SEC Filing Form 4 Vaxcyte, Inc. For: May 01 Filed by: Wassil Jim May 1, 2026 5:38 PM - SEC Filing Form 144 Vaxcyte, Inc. Filed by: Wassil Jim May 1, 2026 4:18 PM - SEC Filing Form SCHEDULE 13G Vaxcyte, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 30, 2026 2:24 PM - SEC Filing Form ARS Vaxcyte, Inc. For: Dec 31 April 23, 2026 7:09 PM - SEC Filing Form DEFA14A Vaxcyte, Inc. April 23, 2026 7:09 PM - SEC Filing Form DEF 14A Vaxcyte, Inc. For: Jun 15 April 23, 2026 7:08 PM - SEC Filing Form 4 Vaxcyte, Inc. For: Apr 07 Filed by: Cowan Elvia April 8, 2026 4:33 PM - SEC Filing Form 144 Vaxcyte, Inc. Filed by: Cowan Elvia April 7, 2026 4:24 PM - SEC Filing Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference April 7, 2026 4:05 PM - StreetInsider Form 4 Vaxcyte, Inc. For: Apr 01 Filed by: Wassil Jim April 3, 2026 4:06 PM - SEC Filing Form 144 Vaxcyte, Inc. Filed by: Wassil Jim April 1, 2026 4:09 PM - SEC Filing Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: VANGUARD GROUP INC March 27, 2026 1:56 PM - SEC Filing Vera Therapeutics names Jane Wright-Mitchell as chief legal officer March 25, 2026 7:30 AM - StreetInsider Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer March 25, 2026 7:30 AM - StreetInsider Vaxcyte completes enrollment for two Phase 3 trials of VAX-31 vaccine March 23, 2026 8:30 AM - StreetInsider Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults March 23, 2026 8:30 AM - StreetInsider Vaxcyte publishes positive VAX-31 phase 1/2 data in Lancet study March 18, 2026 7:34 PM - StreetInsider Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate March 18, 2026 7:34 PM - Globe NewsWire Form 4 Vaxcyte, Inc. For: Mar 17 Filed by: Cowan Elvia March 18, 2026 7:03 PM - SEC Filing Form 144 Vaxcyte, Inc. Filed by: Cowan Elvia March 17, 2026 4:16 PM - SEC Filing Form 4 Vaxcyte, Inc. For: Mar 09 Filed by: Dhaliwal Harpreet S. March 11, 2026 5:25 PM - SEC Filing Form 4 Vaxcyte, Inc. For: Mar 09 Filed by: PICKERING GRANT March 11, 2026 5:25 PM - SEC Filing Form 4 Vaxcyte, Inc. For: Mar 09 Filed by: GUGGENHIME ANDREW March 11, 2026 5:25 PM - SEC Filing Form 4 Vaxcyte, Inc. For: Mar 09 Filed by: Cowan Elvia March 11, 2026 5:24 PM - SEC Filing Form 4 Vaxcyte, Inc. For: Mar 09 Filed by: Wassil Jim March 11, 2026 5:23 PM - SEC Filing Form 144 Vaxcyte, Inc. Filed by: Cowan Elvia March 11, 2026 4:07 PM - SEC Filing Form 144 Vaxcyte, Inc. Filed by: Wassil Jim March 10, 2026 4:12 PM - SEC Filing Jefferies Reiterates Buy Rating on Vaxcyte (PCVX): "adult PCV alone increasingly supports a materially higher long-term valuation" March 10, 2026 12:08 PM - StreetInsider Full Article List